Advent International has agreed to acquire a controlling position in Bharat Serums and Vaccines, an Indian biopharmaceuticals supplier focused on the women’s health segment.
Unison Capital has agreed to buy Kyowa Pharmaceutical Industry, a Japanese subsidiary of India-headquartered drug manufacturer Lupin for an enterprise valuation of JPY57.4 billion ($526 million).
Ontario Teachers' Pension Plan is the sole LP co-investor in BGH Capital's acquisition of Abano Healthcare by virtue of its previous experience with dentistry chain assets
Chinese medical instrument provider Peijia Medical has raised a RMB700 million ($100 million) Series C round from a group including Matrix Partners China and Lilly Asia Ventures.
China International Capital Corporation (CICC) and global pharmaceutical giant AstraZeneca are looking to raise $1 billion for a fund that will back Chinese healthcare companies as well as international players looking to enter the country.
Akeso Biopharma, a Chinese biotech company specializing in antibody drugs, has raised a $150 million Series D round led by Loyal Valley Capital and Sino Biopharm.
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
Ascentage Pharma saw its share price surge 57% during the first day of trading in Hong Kong before closing up 9.9%, following a heavily oversubscribed HK$416.6 million ($53 million) IPO.
Fountain Medical Development, a China-based contract research organization (CRO) that serves a global client base of drug developers, has received $62 million in Series D funding led by Goldman Sachs.
ARQ Capital, a Philippines-based GP focused on the local small to medium-sized enterprise (SME) sector, has invested an undisclosed sum in dialysis clinic operator Medline.
Germany-based life sciences and healthcare technology giant Merck has launched a RMB100 million ($14.1 million) seed fund targeting Chinese start-ups.
Taimei Technology, a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations (CROs) has raised RMB1.5 billion ($212 million) through an extended Series E round of funding.
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.
Indonesian insurer Sequis Life has led a $33 million Series C round of funding for Alodokter, a local super app operator that connects patients with doctors and healthcare information.
Aesthetic Medical International Holdings, a Chinese cosmetic surgery chain that failed to get traction with a Hong Kong IPO four years ago, has filed to list in the US. Its private equity backers include IDG Capital and ADV Partners.
Mingyi Zhonghe, a software-as-a-service (SaaS) platform serving China’s rural clinics, has secured a RMB100 million ($14 million) Series B round led by Sinovation Ventures. Existing investor Yijing Capital re-upped.
GGV Capital has joined a group of investors in a venture round of undisclosed size for Structo, a Singapore-based 3D printing company focused on the dental industry.
A KKR-led consortium has agreed to invest PHP35.3 billion ($680 million) in Metro Pacific Hospital Holdings (MPHH), prompting the Philippines-based hospital operator to abandon immediate plans for an IPO.
AI Medical Service, a Japanese healthcare technology start-up working on what it claims is the world’s first artificial intelligence-enabled endoscopic diagnosis system, has raised JPY4.6 billion ($43 million) in Series B funding.
Gene+ Technology, a Chinese provider of gene sequencing services used to support cancer diagnoses, has raised RMB200 million ($28 million) in a Series B round led by Co-Stone Asset Management.
US private equity firm New Mountain Capital has agreed to acquire Emids, a US-headquartered business process outsourcing (BPO) provider with extensive operations in India, for an undisclosed sum.
New Zealand dairy group Fonterra has agreed to sell its stake in DFE Pharma, a 50-50 joint venture with Royal FrieslandCampina of the Netherlands, to CVC Capital Partners for NZ$633 million ($398 million).
Centurium Capital, CITIC Capital and Hillhouse Capital are part of an investor group targeting a $4.6 billion take-private of China Biologic – just over a year after committing new equity to the US-listed company to protect it from other would-be acquirers.
Most healthcare-focused artificial intelligence start-ups in China focus on image-based diagnosis assistance, but deep learning-based drug discovery might be the key application